ITMI20050328A1 - Composti peptidomimetrici e preparazione di derivati biologicamente attivi - Google Patents

Composti peptidomimetrici e preparazione di derivati biologicamente attivi

Info

Publication number
ITMI20050328A1
ITMI20050328A1 IT000328A ITMI20050328A ITMI20050328A1 IT MI20050328 A1 ITMI20050328 A1 IT MI20050328A1 IT 000328 A IT000328 A IT 000328A IT MI20050328 A ITMI20050328 A IT MI20050328A IT MI20050328 A1 ITMI20050328 A1 IT MI20050328A1
Authority
IT
Italy
Prior art keywords
preparation
compounds
peptidomimetric
biologically active
active derivatives
Prior art date
Application number
IT000328A
Other languages
English (en)
Inventor
Daniela Arosio
Leonardo Manzoni
Carlo Scolastico
Original Assignee
Univ Degli Studi Milano
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Degli Studi Milano filed Critical Univ Degli Studi Milano
Priority to IT000328A priority Critical patent/ITMI20050328A1/it
Priority to EP06744433.1A priority patent/EP1853605B1/en
Priority to AU2006219674A priority patent/AU2006219674A1/en
Priority to PCT/IB2006/000455 priority patent/WO2006095234A2/en
Priority to US11/883,880 priority patent/US20080139461A1/en
Priority to SI200631838T priority patent/SI1853605T1/sl
Priority to PCT/IB2006/000460 priority patent/WO2006092722A1/en
Priority to US11/885,353 priority patent/US8636977B2/en
Priority to CA002599876A priority patent/CA2599876A1/en
Priority to KR1020077022078A priority patent/KR20080009681A/ko
Priority to DK06744433.1T priority patent/DK1853605T3/en
Priority to RU2007136535/04A priority patent/RU2007136535A/ru
Priority to PT67444331T priority patent/PT1853605E/pt
Priority to ES06744433.1T priority patent/ES2525374T3/es
Priority to CNA200680013640XA priority patent/CN101184755A/zh
Priority to PL06744433T priority patent/PL1853605T3/pl
Priority to JP2007557619A priority patent/JP2008531677A/ja
Priority to EP06710490A priority patent/EP1853603A1/en
Publication of ITMI20050328A1 publication Critical patent/ITMI20050328A1/it
Priority to IL185353A priority patent/IL185353A0/en
Priority to NO20074584A priority patent/NO20074584L/no
Priority to US14/153,706 priority patent/US9409951B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
IT000328A 2005-03-03 2005-03-03 Composti peptidomimetrici e preparazione di derivati biologicamente attivi ITMI20050328A1 (it)

Priority Applications (21)

Application Number Priority Date Filing Date Title
IT000328A ITMI20050328A1 (it) 2005-03-03 2005-03-03 Composti peptidomimetrici e preparazione di derivati biologicamente attivi
KR1020077022078A KR20080009681A (ko) 2005-03-03 2006-03-03 펩티도미메틱 화합물 및 생물학적 활성 유도체의 제조
PT67444331T PT1853605E (pt) 2005-03-03 2006-03-03 Ligandos sintéticos direccionados para integrinas para aplicações em diagnóstico e terapêutica
PCT/IB2006/000455 WO2006095234A2 (en) 2005-03-03 2006-03-03 Integrin targeted synthetic ligands for diagnostic and therapeutic applications
US11/883,880 US20080139461A1 (en) 2005-03-03 2006-03-03 Peptidomimetic Compounds and Preparation of Biologically Active Derivatives
SI200631838T SI1853605T1 (sl) 2005-03-03 2006-03-03 Integrinski ciljni sintetični ligandi za diagnostične in terapevtske aplikacije
PCT/IB2006/000460 WO2006092722A1 (en) 2005-03-03 2006-03-03 Peptidomimetic compounds and preparation of biologically active derivatives
US11/885,353 US8636977B2 (en) 2005-03-03 2006-03-03 Integrin targeted synthetic ligands for diagnostic and therapeutic applications
CA002599876A CA2599876A1 (en) 2005-03-03 2006-03-03 Peptidomimetic compounds and preparation of biologically active derivatives
EP06744433.1A EP1853605B1 (en) 2005-03-03 2006-03-03 Integrin targeted synthetic ligands for diagnostic and therapeutic applications
DK06744433.1T DK1853605T3 (en) 2005-03-03 2006-03-03 INTEGRIN-TARGETED SYNTHETIC LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS
RU2007136535/04A RU2007136535A (ru) 2005-03-03 2006-03-03 Пептидомиметические соединения и получение биологически активных производных
AU2006219674A AU2006219674A1 (en) 2005-03-03 2006-03-03 Peptidomimetic compounds and preparation of biologically active derivatives
ES06744433.1T ES2525374T3 (es) 2005-03-03 2006-03-03 Ligandos sintéticos dirigidos a integrinas para aplicaciones diagnósticas y terapéuticas
CNA200680013640XA CN101184755A (zh) 2005-03-03 2006-03-03 肽拟似化合物及生物活性衍生物的制备
PL06744433T PL1853605T3 (pl) 2005-03-03 2006-03-03 Ukierunkowane na integrynę syntetyczne ligandy do zastosowań diagnostycznych i terapeutycznych
JP2007557619A JP2008531677A (ja) 2005-03-03 2006-03-03 ペプチド様化合物及び生物活性誘導体の製造
EP06710490A EP1853603A1 (en) 2005-03-03 2006-03-03 Peptidomimetic compounds and preparation of biologically active derivatives
IL185353A IL185353A0 (en) 2005-03-03 2007-08-19 Azabicycloalkane derivatives , pharmaceutical compositions containing the same and methods for the preparation thereof
NO20074584A NO20074584L (no) 2005-03-03 2007-09-11 Peptidomimetiske forbindelser og fremstilling av biologisk aktive derivater
US14/153,706 US9409951B2 (en) 2005-03-03 2014-01-13 Integrin targeted synthetic ligands for diagnostic and therapeutic applications

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000328A ITMI20050328A1 (it) 2005-03-03 2005-03-03 Composti peptidomimetrici e preparazione di derivati biologicamente attivi

Publications (1)

Publication Number Publication Date
ITMI20050328A1 true ITMI20050328A1 (it) 2006-09-04

Family

ID=36570882

Family Applications (1)

Application Number Title Priority Date Filing Date
IT000328A ITMI20050328A1 (it) 2005-03-03 2005-03-03 Composti peptidomimetrici e preparazione di derivati biologicamente attivi

Country Status (17)

Country Link
US (3) US20080139461A1 (it)
EP (2) EP1853603A1 (it)
JP (1) JP2008531677A (it)
KR (1) KR20080009681A (it)
CN (1) CN101184755A (it)
AU (1) AU2006219674A1 (it)
CA (1) CA2599876A1 (it)
DK (1) DK1853605T3 (it)
ES (1) ES2525374T3 (it)
IL (1) IL185353A0 (it)
IT (1) ITMI20050328A1 (it)
NO (1) NO20074584L (it)
PL (1) PL1853605T3 (it)
PT (1) PT1853605E (it)
RU (1) RU2007136535A (it)
SI (1) SI1853605T1 (it)
WO (2) WO2006092722A1 (it)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20050328A1 (it) * 2005-03-03 2006-09-04 Univ Degli Studi Milano Composti peptidomimetrici e preparazione di derivati biologicamente attivi
US8986650B2 (en) 2005-10-07 2015-03-24 Guerbet Complex folate-NOTA-Ga68
EP1940841B9 (fr) 2005-10-07 2017-04-19 Guerbet Composes comprenant une partie de reconnaissance d'une cible biologique, couplee a une partie de signal capable de complexer le gallium
WO2008040332A1 (de) * 2006-09-25 2008-04-10 Forschungsverbund Berlin E.V. Strukturmimetika prolinreicher peptide und ihre pharmazeutische verwendung
EP1961759A1 (en) * 2007-02-21 2008-08-27 Universita'degli Studi Di Milano Integrin targeted cyclopeptide ligands, their preparation and use
JP2010526091A (ja) * 2007-04-30 2010-07-29 インテザイン テクノロジーズ， インコーポレイテッド 癌の処置のための生物学的な標的基の改変
EP2065058A1 (en) * 2007-11-28 2009-06-03 Koninklijke Philips Electronics N.V. Non-spherical contrast agents for CEST MRI based on bulk magnetic susceptibility effect
EP2127640A1 (en) 2008-05-27 2009-12-02 Koninklijke Philips Electronics N.V. Azide modified proteins
FR2942227B1 (fr) 2009-02-13 2011-04-15 Guerbet Sa Utilisation de tampons pour la complexation de radionucleides
US8920775B2 (en) 2009-07-17 2014-12-30 Technical University Of Denmark Loading technique for preparing radionuclide containing nanoparticles
GB0922014D0 (en) * 2009-12-17 2010-02-03 Ge Healthcare Ltd Novel integrin binders
FR2968662B1 (fr) 2010-12-10 2013-11-22 Roussy Inst Gustave Nouveaux derives d'oxazaphosphorines pre-activees, utilisation et methode de preparation
KR20140092226A (ko) 2010-12-14 2014-07-23 테크니칼 유니버시티 오브 덴마크 나노입자 조성물에서 방사성 핵종의 포집
CN104619717B (zh) * 2012-06-22 2019-04-02 米梅奥亨制药公司 β-转角模拟肽环状化合物的合成
CN107206108B (zh) 2014-12-19 2021-08-31 伯拉考成像股份公司 术中成像
WO2017112809A1 (en) 2015-12-21 2017-06-29 Taxas Tech University System System and method for solution phase gap peptide synthesis
EP4252629A3 (en) 2016-12-07 2023-12-27 Biora Therapeutics, Inc. Gastrointestinal tract detection methods, devices and systems
CN116712540A (zh) 2016-12-14 2023-09-08 比奥拉治疗股份有限公司 使用整联蛋白抑制剂治疗胃肠道疾病
US10870649B2 (en) * 2017-04-13 2020-12-22 Bracco Imaging Spa Synthesis of NIR fluorescent probe
JP2021505618A (ja) * 2017-12-06 2021-02-18 ブラッコ・イメージング・ソシエタ・ペル・アチオニＢｒａｃｃｏ Ｉｍａｇｉｎｇ Ｓ．Ｐ．Ａ． Ｎｉｒ蛍光プローブの固相合成
US12024537B2 (en) 2018-05-31 2024-07-02 Sederma Compositions and methods for chemical synthesis
CN112236436B (zh) * 2018-05-31 2024-03-29 赛德玛公司 一种用于溶液相肽合成的方法及其保护策略
US20230033021A1 (en) 2018-06-20 2023-02-02 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
KR20210095165A (ko) 2018-11-19 2021-07-30 프로제너티, 인크. 바이오의약품으로 질환을 치료하기 위한 방법 및 디바이스
EP3917937A4 (en) * 2019-02-01 2022-11-23 Sederma SYNTHETIC STRATEGY FOR A SPLIT PROTECTION GROUP
CN115666704A (zh) 2019-12-13 2023-01-31 比奥拉治疗股份有限公司 用于将治疗剂递送至胃肠道的可摄取装置

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268486A (en) 1986-04-18 1993-12-07 Carnegie-Mellon Unversity Method for labeling and detecting materials employing arylsulfonate cyanine dyes
DE4445065A1 (de) 1994-12-07 1996-06-13 Diagnostikforschung Inst Verfahren zur In-vivo-Diagnostik mittels NIR-Strahlung
US6018503A (en) 1996-07-05 2000-01-25 Edouard Pfister Time zone indicator device
AU4412297A (en) 1996-09-10 1998-04-02 Burnham Institute, The Tumor homing molecules, conjugates derived therefrom, and methods of using sa me
US6261537B1 (en) * 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
ITRM20020402A1 (it) 2002-07-29 2004-01-29 Sigma Tau Ind Farmaceuti Derivati fluoro-alchil-ciclopeptidi ad attivita' anti-integrine.
ITMI20031476A1 (it) * 2003-07-18 2005-01-19 Univ Degli Studi Milano Composti peptido-mimetici a struttura azabicicloalcanica comprendenti la sequenza rgd
WO2005019247A2 (en) 2003-08-15 2005-03-03 Board Of Regents, The University Of Texas System Cyclic peptide and imaging compound compositions and uses for targeted imaging and therapy
ITMI20032102A1 (it) * 2003-10-30 2005-04-30 Univ Degli Studi Milano Composti peptidomimetici, procedimento stereoselettivo per la loro preparazione, loro uso come intermedi di sintesi di derivati biologicamente attivi.
WO2005123768A1 (en) 2004-06-16 2005-12-29 Ge Healthcare As Peptide-based compounds
ITMI20050328A1 (it) * 2005-03-03 2006-09-04 Univ Degli Studi Milano Composti peptidomimetrici e preparazione di derivati biologicamente attivi
EP1961759A1 (en) 2007-02-21 2008-08-27 Universita'degli Studi Di Milano Integrin targeted cyclopeptide ligands, their preparation and use
MX2011004252A (es) 2008-10-23 2012-01-27 Steba Biotech N V Peptidomiméticos que contienen arginina-glicina-ácido aspártato y usos de los mismos.
WO2010076334A2 (en) 2008-12-31 2010-07-08 Centre Leon Berard Intraoperative diagnosis of primary tumors and secondary tumors or metastases
EP2457593A1 (en) 2010-11-08 2012-05-30 Lykera Biomed S.A. Cyclic RGD peptides of amino acids based on thiazoles or oxazoles as selective antagonists of the alpha-v beta-3 integrin

Also Published As

Publication number Publication date
WO2006092722A8 (en) 2008-01-31
AU2006219674A1 (en) 2006-09-08
IL185353A0 (en) 2008-02-09
US8636977B2 (en) 2014-01-28
PT1853605E (pt) 2014-12-03
JP2008531677A (ja) 2008-08-14
SI1853605T1 (sl) 2014-12-31
US20080139461A1 (en) 2008-06-12
WO2006095234A2 (en) 2006-09-14
EP1853605A2 (en) 2007-11-14
DK1853605T3 (en) 2014-12-15
US20080317668A1 (en) 2008-12-25
PL1853605T3 (pl) 2015-02-27
EP1853605B1 (en) 2014-09-10
ES2525374T3 (es) 2014-12-23
RU2007136535A (ru) 2009-04-10
NO20074584L (no) 2007-09-27
WO2006092722A1 (en) 2006-09-08
CN101184755A (zh) 2008-05-21
EP1853603A1 (en) 2007-11-14
US20140178302A1 (en) 2014-06-26
WO2006095234A3 (en) 2006-12-07
CA2599876A1 (en) 2006-09-08
KR20080009681A (ko) 2008-01-29
US9409951B2 (en) 2016-08-09

Similar Documents

Publication Publication Date Title
ITMI20050328A1 (it) Composti peptidomimetrici e preparazione di derivati biologicamente attivi
CY1109010T1 (el) γ-ΚΡΥΣΤΑΛΛΙΚΗ ΜΟΡΦΗ ΤΗΣ ΥΔΡΟΧΛΩΡΙΚΗΣ ΙΒΑΒΡΑΔΙΝΗΣ, ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΤΗΣ ΚΑΙ ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΘΕΣΕΙΣ ΠΟΥ ΤΗΝ ΠΕΡΙΕΧΟΥΝ
BRPI0620436B8 (pt) compostos miméticos de lisina modificados, composição farmacêutica e uso
BRPI0605921B8 (pt) compostos orgânicos, seus métodos de preparo e uso, bem como composições farmacêuticas
CY1112886T1 (el) Ανοσοκατασταλτικος παραγοντας ο οποιος περιλαμβανει μια ετεροκυκλικη ενωση ως δραστικο συστατικο
EA201692543A1 (ru) Антагонисты активина-actriia и их применение для стимулирования роста кости
UY29856A1 (es) Forma cristalina 8d del clorhidrato de la ivabradina, su procedimiento de preparación, y las composiciones farmaceuticas que la contienen
CL2004000788A1 (es) Compuestos derivados de n-[2-oxo-6-(aril o heteroaril)azepan-3-il]-4-(2-oxo-2,3-dihidro-1h-imidazo[4,5-b]piridin-1-il)piperidina-1-carboxamida, antagonistas de los receptores cgrp; composicion farmaceutica; y uso del compuesto en el tratamiento del d
DE502005009389D1 (de) Identifizierung und charakterisierung von funktionsblockierenden anti-ed-b-fibronektin antikörpern
ATE496884T1 (de) Sulphonylaminoessigsaeure derivate und deren verwendung als orexin rezeptor antagoniste
BRPI0507680A (pt) partìculas de fosfato de cálcio terapêuticas e métodos de fabricação e uso das mesmas
MA29135B1 (fr) Potentialisateurs de recepteurs du glutamate
BRPI0920108A2 (pt) peptídomimético cíclico contendo argina, glicina, ácido aspártico (rgd), conjugado de peptidomimético cíclico contendo rgd, composição farmacêutica, conjugado e uso do mesmo.
DE602006020871D1 (de) Lineare harnstoffmimetika-antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden
ATE497774T1 (de) Screening kombinatorischer proteinbibliotheken mittels periplasmatischer expression
EA200701293A1 (ru) Терапевтическая композиция фактора роста кератиноцитов
UY29999A1 (es) "n-pirazinil-fenilsulfonamidas, procedimientos y compuestos intemedios utilizados en su preparacion, composiciones farmaceuticas que las contienen y aplicaciones"
FR2949782B1 (fr) Peptide activateur de la transglutaminase et composition cosmetique ou pharmaceutique le contenant.
UY27514A1 (es) Compuestos basicos lineales que tienen actividad antagonista de nk-2 y sus formulaciones.
SE0402284D0 (sv) New heterocyclic amides
ATE373637T1 (de) N-(2-phenylethyl)sulfamid-derivate als integrin- alpha4-antagonisten
FR2940291B1 (fr) Peptide derive d'hmg-coa reductase et composition cosmetique ou pharmaceutique le contenant
BRPI0318325B8 (pt) compostos miméticos de beta-fita
EA201001568A1 (ru) Инкапсуляция биологически активных агентов
ITMI20051634A1 (it) Perno per l'ancoraggio di protesi articolari e protesi articolare comprendente tale perno